cohort study.25 Cardiovascular (CV) events Following the post-authorization ORAL Surveillance trial of tofacitinib in rheumatoid arthritis,29 it was recognized that JAK inhibitors may increase the risk of thrombosis, major adverse cardiovascular events (MACE), malignancy, and mortality in high-risk populations.30,31 However, it is unclear whether these risks apply to ritlecitinib in AA
04 Injection-site reaction Mild redness or swelling at the injection site is the most commonly reported AOD-9604 adverse event in trials
However, some people may struggle to get enough B12 due to dietary restrictions, medical conditions, or age
Chronic conditions that developed over months or years require proportional treatment duration
To eliminate red blood cells (RBCs) and clots, 0.1 mM EDTA was added